- Home
- CADL vs DRTS Comparison
CADL vs DRTS Comparison
Compare CADL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- DRTS
- Stock Information
- Founded
- CADL 1999
- DRTS 2015
- Country
- CADL United States
- DRTS Israel
- Employees
- CADL N/A
- DRTS N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- CADL Health Care
- DRTS Health Care
- Exchange
- CADL Nasdaq
- DRTS Nasdaq
- Market Cap
- CADL 339.8M
- DRTS 300.2M
- IPO Year
- CADL 2021
- DRTS N/A
- Fundamental
- Price
- CADL $5.64
- DRTS $3.90
- Analyst Decision
- CADL Strong Buy
- DRTS Strong Buy
- Analyst Count
- CADL 7
- DRTS 1
- Target Price
- CADL $19.57
- DRTS $9.00
- AVG Volume (30 Days)
- CADL 841.7K
- DRTS 62.1K
- Earning Date
- CADL 11-14-2025
- DRTS 11-18-2025
- Dividend Yield
- CADL N/A
- DRTS N/A
- EPS Growth
- CADL N/A
- DRTS N/A
- EPS
- CADL N/A
- DRTS N/A
- Revenue
- CADL N/A
- DRTS N/A
- Revenue This Year
- CADL N/A
- DRTS N/A
- Revenue Next Year
- CADL N/A
- DRTS N/A
- P/E Ratio
- CADL N/A
- DRTS N/A
- Revenue Growth
- CADL N/A
- DRTS N/A
- 52 Week Low
- CADL $3.79
- DRTS $2.14
- 52 Week High
- CADL $14.60
- DRTS $4.69
- Technical
- Relative Strength Index (RSI)
- CADL 51.71
- DRTS 46.15
- Support Level
- CADL $5.35
- DRTS $3.80
- Resistance Level
- CADL $5.80
- DRTS $4.50
- Average True Range (ATR)
- CADL 0.37
- DRTS 0.24
- MACD
- CADL -0.01
- DRTS -0.03
- Stochastic Oscillator
- CADL 42.40
- DRTS 20.00
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.